Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Bristol-Myers Squibb Company

BMY
Current price
59.01 USD -0.83 USD (-1.39%)
Last closed 60.28 USD
ISIN US1101221083
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NYSE
Capitalization 116 275 560 448 USD
Yield for 12 month +12.74 %
1Y
3Y
5Y
10Y
15Y
BMY
21.11.2021 - 28.11.2021

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey. Address: Route 206 & Province Line Road, Princeton, NJ, United States, 08543

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

60.91 USD

P/E ratio

Dividend Yield

4.20 %

Current Year

+45 006 000 000 USD

Last Year

+46 159 000 000 USD

Current Quarter

+11 892 000 000 USD

Last Quarter

+12 201 000 000 USD

Current Year

+34 313 000 000 USD

Last Year

+36 022 000 000 USD

Current Quarter

+8 935 000 000 USD

Last Quarter

+6 801 000 000 USD

Key Figures BMY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 19 161 999 360 USD
Operating Margin TTM 18.48 %
Price to Earnings
Return On Assets TTM 6.07 %
PEG Ratio 1.97
Return On Equity TTM -31.33 %
Wall Street Target Price 60.91 USD
Revenue TTM 47 435 001 856 USD
Book Value 8.45 USD
Revenue Per Share TTM
Dividend Share 2.40 USD
Quarterly Revenue Growth YOY 8.40 %
Dividend Yield 4.20 %
Gross Profit TTM 36 378 000 000 USD
Earnings per share -3.58 USD
Diluted Eps TTM -3.58 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY -35.80 %
Profit Margin -15.30 %

Dividend Analytics BMY

Champion - 10+ consecutive years of dividend increases

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

46.00 %

Consecutive Years

17 years

5Y Average Payout Ratio

98.00 %

Dividend History BMY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date 03.01.2025
Dividend CAGR 3Y 17.75 %
Dividend CAGR 5Y 7.91 %
Dividend CAGR 10Y 5.17 %
Consecutive Years 17
Consistent Years 27
Continuous Dividends 53
Forward Annual Dividend Yield 4.33 %
Forward Annual Dividend 2.48 USD
Last Split Factor 1000000:95
Payout Ratio 2.28 %
Last Split Date 07.08.2001

Stock Valuation BMY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 8.08
Enterprise Value Revenue 3.36
Price Sales TTM 2.45
Enterprise Value EBITDA 31.47
Price Book MRQ 6.78

Financials BMY

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BMY

For 52 weeks

38.60 USD 61.08 USD
50 Day MA 56.13 USD
Shares Short Prior Month 23 421 095
200 Day MA 49.22 USD
Short Ratio 2.16
Shares Short 25 600 720
Short Percent 1.26 %